The feed
GLP-1 briefs
Dated, plain-English notes on what actually moved this cycle — prices, supply, and provider changes across the GLP-1 telehealth market. Newest first. Each brief links onward to the underlying provider brief or the Brief Score methodology.
- Price
Low monthly GLP-1 prices can require a year upfront
A low monthly equivalent can mean a large upfront payment. Our August 28 comparison found that 11 of 17 partner price listings needed correction or more context.
- Policy
The GLP-1 pill is no longer a pipeline story
Two oral GLP-1s are now FDA-approved for weight management: the Wegovy pill in December 2025 and Foundayo, the first small-molecule GLP-1 built to be swallowed, on April 1, 2026.
- Price
A flat monthly equivalent can still mean annual prepayment
Compare renewal rates and payment schedules together. A first-month discount can rise at renewal, while a low annual-plan equivalent may require paying the whole year upfront.
- Supply
Both GLP-1 molecules stay off the FDA shortage list
Brand semaglutide and tirzepatide remain resolved on the FDA drug-shortage database. Compounded supply stays legal but under active regulatory attention, so who your provider sources from still matters.
- Price
A lower tirzepatide price still needs a like-for-like comparison
ShedRx lowered its advertised tirzepatide price, but an August correction established it was not the lowest among our partners. Compare formulation and commitment as well as price.
- Provider
A flat-fee pioneer drifts to the top of the price ranking
The provider that popularized flat-fee compounded GLP-1 now prices at the higher end of our tracker, a reminder that 'the original' is not automatically the cheapest anymore.
- Policy
How we score a provider's price stability
Price Stability is the heaviest factor in the Brief Score. Here is exactly how a steady, no-surprise monthly line earns points — and how a teaser rate that silently triples loses them.
Briefs are dated market observations, revised as the story moves — not timeless fact, and not medical advice. Confirm any current price or supply status at the source.